JP2024026255A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024026255A5 JP2024026255A5 JP2023204313A JP2023204313A JP2024026255A5 JP 2024026255 A5 JP2024026255 A5 JP 2024026255A5 JP 2023204313 A JP2023204313 A JP 2023204313A JP 2023204313 A JP2023204313 A JP 2023204313A JP 2024026255 A5 JP2024026255 A5 JP 2024026255A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid position
- domain
- tyrosine
- binding polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025179195A JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622468P | 2018-01-26 | 2018-01-26 | |
| US62/622,468 | 2018-01-26 | ||
| JP2020561607A JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| PCT/US2019/015204 WO2019147973A1 (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561607A Division JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179195A Division JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024026255A JP2024026255A (ja) | 2024-02-28 |
| JP2024026255A5 true JP2024026255A5 (enExample) | 2024-09-05 |
| JP7860946B2 JP7860946B2 (ja) | 2026-05-18 |
Family
ID=65520379
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561607A Active JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2023204313A Active JP7860946B2 (ja) | 2018-01-26 | 2023-12-04 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2025179195A Pending JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561607A Active JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179195A Pending JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190263934A1 (enExample) |
| EP (1) | EP3743441A1 (enExample) |
| JP (3) | JP7399880B2 (enExample) |
| KR (2) | KR20250008975A (enExample) |
| CN (3) | CN119350481A (enExample) |
| AU (2) | AU2019212638B2 (enExample) |
| BR (1) | BR112020015006A2 (enExample) |
| CA (1) | CA3089602A1 (enExample) |
| CO (1) | CO2020010269A2 (enExample) |
| IL (2) | IL318916A (enExample) |
| MX (2) | MX2020007882A (enExample) |
| MY (1) | MY203898A (enExample) |
| PH (1) | PH12020551134A1 (enExample) |
| SG (1) | SG11202006905YA (enExample) |
| WO (1) | WO2019147973A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020015006A2 (pt) * | 2018-01-26 | 2020-12-29 | Genzyme Corporation | Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada |
| CN114466663B (zh) * | 2019-07-25 | 2026-01-02 | 建新公司 | 以FcRn拮抗剂治疗抗体介导的障碍的方法 |
| AU2020358854B2 (en) | 2019-10-03 | 2026-08-13 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| JP7832123B2 (ja) * | 2020-05-11 | 2026-03-17 | インベテックス インコーポレイテッド | 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法 |
| WO2022090469A2 (en) * | 2020-10-29 | 2022-05-05 | Formycon Ag | Ace2 fusion proteins and uses thereof |
| TW202306584A (zh) | 2021-05-27 | 2023-02-16 | 法商賽諾菲公司 | 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體 |
| WO2023021169A1 (en) | 2021-08-20 | 2023-02-23 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
| US20240409618A1 (en) * | 2021-10-13 | 2024-12-12 | The Wistar Institute Of Anatomy And Biology | DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS |
| WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| CN116162171B (zh) * | 2022-10-13 | 2025-06-03 | 深圳市百士通科技开发有限公司 | 抗体突变方法在治疗性抗体药物中的应用 |
| JP2026513101A (ja) | 2022-10-25 | 2026-04-23 | アブリンクス エン．ヴェー． | エフェクター機能が強化された糖鎖改変Ｆｃ変異ポリペプチド |
| TW202432602A (zh) | 2022-12-05 | 2024-08-16 | 法商賽諾菲公司 | 運鐵蛋白受體結合蛋白 |
| WO2025088546A1 (en) | 2023-10-25 | 2025-05-01 | Ablynx N.V. | Fc domain variants with enhanced fc receptor binding |
| WO2025101094A1 (en) * | 2023-11-08 | 2025-05-15 | Ооо «Geropharm» | Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
| TW202619716A (zh) | 2024-07-23 | 2026-05-16 | 法商賽諾菲公司 | Ｃｅｒｅｂｌｏｎ連接酶調節劑與ｂｃｍａ ｎｋ細胞銜接子的組合療法 |
| WO2026125322A1 (en) | 2024-12-10 | 2026-06-18 | Intervet International B.V. | CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE |
| WO2026125320A1 (en) | 2024-12-10 | 2026-06-18 | Intervet International B.V. | Caninized il31rα antibodies with an extended half life |
| WO2026125321A1 (en) | 2024-12-10 | 2026-06-18 | Intervet International B.V. | Caninized il31rα antibodies with an extended half life |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| HUP0104865A3 (en) * | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| CA2577133A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US9200079B2 (en) * | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) * | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8775090B2 (en) * | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
| ES2573642T3 (es) * | 2009-12-23 | 2016-06-09 | Synimmune Gmbh | Anticuerpos anti-FLT3 y métodos de usar los mismos |
| WO2011089211A1 (en) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| JP6322411B2 (ja) * | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| CA2904805A1 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| PT3215528T (pt) * | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Variantes da região fc com ligação modificada ao fcrn e métodos de utilização |
| SG11201702550WA (en) * | 2014-11-10 | 2017-04-27 | Hoffmann La Roche | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| CA3032820A1 (en) * | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| BR112020015006A2 (pt) | 2018-01-26 | 2020-12-29 | Genzyme Corporation | Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada |
-
2019
- 2019-01-25 BR BR112020015006-1A patent/BR112020015006A2/pt unknown
- 2019-01-25 CN CN202411307275.XA patent/CN119350481A/zh active Pending
- 2019-01-25 JP JP2020561607A patent/JP7399880B2/ja active Active
- 2019-01-25 CN CN202610126479.6A patent/CN122145612A/zh active Pending
- 2019-01-25 CA CA3089602A patent/CA3089602A1/en active Pending
- 2019-01-25 EP EP19707152.5A patent/EP3743441A1/en active Pending
- 2019-01-25 IL IL318916A patent/IL318916A/en unknown
- 2019-01-25 AU AU2019212638A patent/AU2019212638B2/en active Active
- 2019-01-25 KR KR1020247043107A patent/KR20250008975A/ko active Pending
- 2019-01-25 US US16/258,080 patent/US20190263934A1/en active Pending
- 2019-01-25 CN CN201980015900.4A patent/CN111788221B/zh active Active
- 2019-01-25 MY MYPI2020003848A patent/MY203898A/en unknown
- 2019-01-25 SG SG11202006905YA patent/SG11202006905YA/en unknown
- 2019-01-25 IL IL276286A patent/IL276286B2/en unknown
- 2019-01-25 WO PCT/US2019/015204 patent/WO2019147973A1/en not_active Ceased
- 2019-01-25 MX MX2020007882A patent/MX2020007882A/es unknown
- 2019-01-25 KR KR1020207024432A patent/KR102748986B1/ko active Active
-
2020
- 2020-07-24 PH PH12020551134A patent/PH12020551134A1/en unknown
- 2020-07-24 MX MX2025009543A patent/MX2025009543A/es unknown
- 2020-08-20 CO CONC2020/0010269A patent/CO2020010269A2/es unknown
-
2023
- 2023-12-04 JP JP2023204313A patent/JP7860946B2/ja active Active
-
2025
- 2025-06-26 AU AU2025204826A patent/AU2025204826A1/en active Pending
- 2025-10-24 JP JP2025179195A patent/JP2026021377A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021511830A5 (enExample) | ||
| IL276286B2 (en) | FC variants with improved binding to FCRN and extended half-life | |
| CN110382529B (zh) | 工程化的异源二聚体蛋白质 | |
| JP6435193B2 (ja) | 抗体を精製する方法 | |
| JP7566856B2 (ja) | 多重特異的抗体を調製するためのポリペプチドリンカー | |
| CN113227134A (zh) | 抗体的Fc区变体 | |
| CA2502904A1 (en) | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis | |
| JP2012515556A5 (enExample) | ||
| KR20120107140A (ko) | 면역글로불린 용액 정제 방법 | |
| US11945839B2 (en) | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography | |
| WO2021047559A1 (zh) | 一种断裂型内含肽、使用其的重组多肽的制备方法 | |
| CN106459191B (zh) | 选择具有修饰的FcRn相互作用的抗体的方法 | |
| WO2022166728A1 (zh) | 双特异性抗体 | |
| TW201716442A (zh) | 抗EphA4抗體 | |
| JP2023526630A (ja) | Ｉｇ様分子の製造のための方法および手段 | |
| JP2024507693A5 (enExample) | ||
| JP2023508366A (ja) | 二重特異性ｆｃｙｒｉｉｉ×ｃｄ３０抗体構築体の製造方法 | |
| JP2024531346A5 (enExample) | ||
| JP2025517120A5 (enExample) | ||
| TW202204423A (zh) | 用於產生和純化多價免疫球蛋白單可變域的方法 | |
| JP2024522092A5 (enExample) | ||
| JP7796415B2 (ja) | エリスロポエチンポリペプチドを含む融合タンパク質 | |
| JP2022512798A (ja) | 抗体ＦｃＲｎ結合の改変 | |
| KR20260065533A (ko) | FcRn과 pH 선택적 결합능을 갖는 짧은 펩타이드 | |
| NZ767453B2 (en) | Fc variants with enhanced binding to fcrn and prolonged half-life |